Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01777152
Registration number
NCT01777152
Ethics application status
Date submitted
23/01/2013
Date registered
28/01/2013
Date last updated
30/11/2021
Titles & IDs
Public title
ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Query!
Scientific title
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in the Frontline Treatment of Patients With CD30-positive Mature T-cell Lymphomas
Query!
Secondary ID [1]
0
0
2012-002751-42
Query!
Secondary ID [2]
0
0
SGN35-014
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
ECHELON-2
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Anaplastic Large-Cell Lymphoma
0
0
Query!
Non-Hodgkin Lymphoma
0
0
Query!
T-Cell Lymphoma
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Query!
Cancer
0
0
0
0
Query!
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - brentuximab vedotin
Treatment: Drugs - doxorubicin
Treatment: Drugs - prednisone
Treatment: Drugs - vincristine
Treatment: Drugs - cyclophosphamide
Active comparator: CHOP - cyclophosphamide, doxorubicin, vincristine, and prednisone
Experimental: A+CHP - brentuximab vedotin, cyclophosphamide, doxorubicin, and prednisone
Treatment: Drugs: brentuximab vedotin
1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
Treatment: Drugs: doxorubicin
50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Treatment: Drugs: prednisone
100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
Treatment: Drugs: vincristine
1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
Treatment: Drugs: cyclophosphamide
750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival Per Independent Review Facility (IRF)
Query!
Assessment method [1]
0
0
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.
Query!
Timepoint [1]
0
0
Up to 60 months
Query!
Secondary outcome [1]
0
0
Progression-free Survival Per IRF in Patients With Systemic Anaplastic Large Cell Lymphoma (sALCL)
Query!
Assessment method [1]
0
0
The time from the date of randomization to the date of first documentation of progressive disease (PD), death due to any cause, or receipt of subsequent anticancer chemotherapy to treat residual or progressive disease whichever occurred first.
Query!
Timepoint [1]
0
0
Up to 60 months
Query!
Secondary outcome [2]
0
0
Complete Remission (CR) Rate Per IRF at End of Treatment (EOT)
Query!
Assessment method [2]
0
0
The count of participants with CR per IRF following the completion of study treatment (at end of treatment or at the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.
Query!
Timepoint [2]
0
0
Up to 8.34 months
Query!
Secondary outcome [3]
0
0
Overall Survival (OS)
Query!
Assessment method [3]
0
0
The time from randomization to death due to any cause.
Query!
Timepoint [3]
0
0
Up to 90 months
Query!
Secondary outcome [4]
0
0
Objective Response Rate (ORR) Per IRF at End of Treatment
Query!
Assessment method [4]
0
0
The count of participants with CR or partial response (PR) per IRF following the completion of study treatment (at end of treatment or the first assessment after the last dose of study treatment and prior to long-term follow-up) according to the Revised Response Criteria for Malignant Lymphoma.
Query!
Timepoint [4]
0
0
Up to 8.34 months
Query!
Secondary outcome [5]
0
0
Incidence of Adverse Events (AEs)
Query!
Assessment method [5]
0
0
Any untoward medical occurrence in a clinical investigational participant administered a medicinal product which does not necessarily have a causal relationship with this treatment.
Query!
Timepoint [5]
0
0
Up to 8.28 months
Query!
Secondary outcome [6]
0
0
Incidence of Laboratory Abnormalities
Query!
Assessment method [6]
0
0
Number of participants who experienced a Grade 3 or higher laboratory toxicity.
Query!
Timepoint [6]
0
0
Up to 8.28 months
Query!
Eligibility
Key inclusion criteria
* Patients with newly diagnosed, CD30-positive mature T-cell lymphomas
* Fluorodeoxyglucose (FDG)-avid disease by PET and measurable disease of at least 1.5 cm by CT
* Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* History of another primary invasive malignancy that has not been in remission for at least 3 years
* Current diagnosis of primary cutaneous CD30-positive T-cell lymphoproliferative disorders and lymphomas or mycosis fungoides
* History of progressive multifocal leukoencephalopathy (PML)
* Cerebral/meningeal disease related to the underlying malignancy
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
31/01/2013
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
2/10/2020
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
452
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Recruitment hospital [1]
0
0
Royal Adelaide Hospital - Adelaide
Query!
Recruitment hospital [2]
0
0
Moorabbin Hospital - Bentleigh East
Query!
Recruitment hospital [3]
0
0
Icon Cancer Care Chermside - Chermside
Query!
Recruitment hospital [4]
0
0
Icon Cancer Care South Brisbane - Chermside
Query!
Recruitment hospital [5]
0
0
Icon Cancer Care Southport - Chermside
Query!
Recruitment hospital [6]
0
0
Icon Cancer Care Wesley - Chermside
Query!
Recruitment hospital [7]
0
0
Monash Medical Centre - Clayton
Query!
Recruitment hospital [8]
0
0
Concord Repatriation General Hospital - Concord
Query!
Recruitment hospital [9]
0
0
St. Vincent's Hospital Sydney - Darlinghurst
Query!
Recruitment hospital [10]
0
0
St Vincent's Public Hospital Sydney - Fitzroy - Fitzroy
Query!
Recruitment hospital [11]
0
0
Western Hospital - Footscray
Query!
Recruitment hospital [12]
0
0
Austin Health - Heidelberg
Query!
Recruitment hospital [13]
0
0
Calvary Mater Newcastle - Waratah
Query!
Recruitment postcode(s) [1]
0
0
5000 - Adelaide
Query!
Recruitment postcode(s) [2]
0
0
3165 - Bentleigh East
Query!
Recruitment postcode(s) [3]
0
0
4032 - Chermside
Query!
Recruitment postcode(s) [4]
0
0
3168 - Clayton
Query!
Recruitment postcode(s) [5]
0
0
2139 - Concord
Query!
Recruitment postcode(s) [6]
0
0
2010 - Darlinghurst
Query!
Recruitment postcode(s) [7]
0
0
3065 - Fitzroy
Query!
Recruitment postcode(s) [8]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [9]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [10]
0
0
2298 - Waratah
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Florida
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Illinois
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Iowa
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Kansas
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Massachusetts
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Missouri
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
New Jersey
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
New York
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Ohio
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Oklahoma
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Pennsylvania
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Tennessee
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Texas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Virginia
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Washington
Query!
Country [18]
0
0
Canada
Query!
State/province [18]
0
0
Montreal
Query!
Country [19]
0
0
Canada
Query!
State/province [19]
0
0
Toronto
Query!
Country [20]
0
0
Canada
Query!
State/province [20]
0
0
Vancouver
Query!
Country [21]
0
0
Czechia
Query!
State/province [21]
0
0
Brno
Query!
Country [22]
0
0
Czechia
Query!
State/province [22]
0
0
Hradec Kralove
Query!
Country [23]
0
0
Czechia
Query!
State/province [23]
0
0
Ostrava - Poruba
Query!
Country [24]
0
0
Czechia
Query!
State/province [24]
0
0
Praha 10
Query!
Country [25]
0
0
Czechia
Query!
State/province [25]
0
0
Praha 2
Query!
Country [26]
0
0
Denmark
Query!
State/province [26]
0
0
Aarhus C.
Query!
Country [27]
0
0
Denmark
Query!
State/province [27]
0
0
Copenhagen
Query!
Country [28]
0
0
Denmark
Query!
State/province [28]
0
0
Odense C
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
Créteil
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
La Roche-sur-Yon Cedex 9
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
La Tronche
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Le Mans
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Lille cedex
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Limoges Cedex
Query!
Country [35]
0
0
France
Query!
State/province [35]
0
0
Nantes cedex 1
Query!
Country [36]
0
0
France
Query!
State/province [36]
0
0
Paris Cedex 10
Query!
Country [37]
0
0
France
Query!
State/province [37]
0
0
Paris
Query!
Country [38]
0
0
France
Query!
State/province [38]
0
0
Pessac
Query!
Country [39]
0
0
France
Query!
State/province [39]
0
0
Pierre Bénite Cedex
Query!
Country [40]
0
0
France
Query!
State/province [40]
0
0
Poitiers Cedex
Query!
Country [41]
0
0
France
Query!
State/province [41]
0
0
Rennes Cedex 9
Query!
Country [42]
0
0
France
Query!
State/province [42]
0
0
Rouen
Query!
Country [43]
0
0
Germany
Query!
State/province [43]
0
0
Berlin
Query!
Country [44]
0
0
Germany
Query!
State/province [44]
0
0
Chemnitz
Query!
Country [45]
0
0
Germany
Query!
State/province [45]
0
0
Essen
Query!
Country [46]
0
0
Germany
Query!
State/province [46]
0
0
Frankfurt am Main
Query!
Country [47]
0
0
Germany
Query!
State/province [47]
0
0
Göttingen
Query!
Country [48]
0
0
Germany
Query!
State/province [48]
0
0
Heidelberg
Query!
Country [49]
0
0
Germany
Query!
State/province [49]
0
0
Homburg/Saar
Query!
Country [50]
0
0
Germany
Query!
State/province [50]
0
0
Jena
Query!
Country [51]
0
0
Germany
Query!
State/province [51]
0
0
Köln
Query!
Country [52]
0
0
Germany
Query!
State/province [52]
0
0
München
Query!
Country [53]
0
0
Germany
Query!
State/province [53]
0
0
Nürnberg
Query!
Country [54]
0
0
Germany
Query!
State/province [54]
0
0
Ulm
Query!
Country [55]
0
0
Hungary
Query!
State/province [55]
0
0
Budapest
Query!
Country [56]
0
0
Hungary
Query!
State/province [56]
0
0
Debrecen
Query!
Country [57]
0
0
Hungary
Query!
State/province [57]
0
0
Kaposvár
Query!
Country [58]
0
0
Hungary
Query!
State/province [58]
0
0
Szombathely
Query!
Country [59]
0
0
Israel
Query!
State/province [59]
0
0
Beer Sheva
Query!
Country [60]
0
0
Israel
Query!
State/province [60]
0
0
Haifa
Query!
Country [61]
0
0
Israel
Query!
State/province [61]
0
0
Jerusalem
Query!
Country [62]
0
0
Israel
Query!
State/province [62]
0
0
Petach Tikva
Query!
Country [63]
0
0
Israel
Query!
State/province [63]
0
0
Tel Aviv
Query!
Country [64]
0
0
Italy
Query!
State/province [64]
0
0
Alessandria
Query!
Country [65]
0
0
Italy
Query!
State/province [65]
0
0
Bergamo
Query!
Country [66]
0
0
Italy
Query!
State/province [66]
0
0
Bologna
Query!
Country [67]
0
0
Italy
Query!
State/province [67]
0
0
Brescia
Query!
Country [68]
0
0
Italy
Query!
State/province [68]
0
0
Catania
Query!
Country [69]
0
0
Italy
Query!
State/province [69]
0
0
Genova
Query!
Country [70]
0
0
Italy
Query!
State/province [70]
0
0
Milano
Query!
Country [71]
0
0
Italy
Query!
State/province [71]
0
0
Pavia
Query!
Country [72]
0
0
Italy
Query!
State/province [72]
0
0
Pesaro
Query!
Country [73]
0
0
Italy
Query!
State/province [73]
0
0
Roma
Query!
Country [74]
0
0
Italy
Query!
State/province [74]
0
0
Rozzano
Query!
Country [75]
0
0
Italy
Query!
State/province [75]
0
0
Torino
Query!
Country [76]
0
0
Italy
Query!
State/province [76]
0
0
Verona
Query!
Country [77]
0
0
Korea, Republic of
Query!
State/province [77]
0
0
Daegu
Query!
Country [78]
0
0
Korea, Republic of
Query!
State/province [78]
0
0
Hwasun
Query!
Country [79]
0
0
Korea, Republic of
Query!
State/province [79]
0
0
Seongnam-si
Query!
Country [80]
0
0
Korea, Republic of
Query!
State/province [80]
0
0
Seoul
Query!
Country [81]
0
0
Poland
Query!
State/province [81]
0
0
Brzozow
Query!
Country [82]
0
0
Poland
Query!
State/province [82]
0
0
Chorzów
Query!
Country [83]
0
0
Poland
Query!
State/province [83]
0
0
Krakow
Query!
Country [84]
0
0
Poland
Query!
State/province [84]
0
0
Warsaw
Query!
Country [85]
0
0
Romania
Query!
State/province [85]
0
0
Bucharest
Query!
Country [86]
0
0
Romania
Query!
State/province [86]
0
0
Bucuresti
Query!
Country [87]
0
0
Romania
Query!
State/province [87]
0
0
Cluj-Napoca
Query!
Country [88]
0
0
Romania
Query!
State/province [88]
0
0
Targu Mures
Query!
Country [89]
0
0
Spain
Query!
State/province [89]
0
0
Barcelona
Query!
Country [90]
0
0
Spain
Query!
State/province [90]
0
0
L'Hospitalet de Llobregat
Query!
Country [91]
0
0
Spain
Query!
State/province [91]
0
0
León
Query!
Country [92]
0
0
Spain
Query!
State/province [92]
0
0
Madrid
Query!
Country [93]
0
0
Spain
Query!
State/province [93]
0
0
Majadahonda
Query!
Country [94]
0
0
Spain
Query!
State/province [94]
0
0
Salamanca
Query!
Country [95]
0
0
Spain
Query!
State/province [95]
0
0
Sevilla
Query!
Country [96]
0
0
Spain
Query!
State/province [96]
0
0
Valencia
Query!
Country [97]
0
0
Taiwan
Query!
State/province [97]
0
0
Kaohsiung
Query!
Country [98]
0
0
Taiwan
Query!
State/province [98]
0
0
Taichung
Query!
Country [99]
0
0
Taiwan
Query!
State/province [99]
0
0
Tainan
Query!
Country [100]
0
0
Taiwan
Query!
State/province [100]
0
0
Taoyuan
Query!
Country [101]
0
0
United Kingdom
Query!
State/province [101]
0
0
Cambridge
Query!
Country [102]
0
0
United Kingdom
Query!
State/province [102]
0
0
Leicester
Query!
Country [103]
0
0
United Kingdom
Query!
State/province [103]
0
0
London
Query!
Country [104]
0
0
United Kingdom
Query!
State/province [104]
0
0
Manchester
Query!
Country [105]
0
0
United Kingdom
Query!
State/province [105]
0
0
Newcastle upon Tyne
Query!
Country [106]
0
0
United Kingdom
Query!
State/province [106]
0
0
Nottingham
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Seagen Inc.
Query!
Address
Query!
Country
Query!
Other collaborator category [1]
0
0
Commercial sector/industry
Query!
Name [1]
0
0
Millennium Pharmaceuticals, Inc.
Query!
Address [1]
0
0
Query!
Country [1]
0
0
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This is a double-blind, randomized, multicenter, phase 3 clinical trial to compare the efficacy and safety of brentuximab vedotin in combination with CHP with the standard-of-care CHOP in patients with CD30-positive mature T-cell lymphomas.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01777152
Query!
Trial related presentations / publications
Savage KJ, Horwitz SM, Advani R, Christensen JH, Domingo-Domenech E, Rossi G, Morschhauser F, Alpdogan O, Suh C, Tobinai K, Shustov A, Trneny M, Yuen S, Zinzani PL, Trumper L, Ilidge T, O'Connor OA, Pro B, Miao H, Bunn V, Fenton K, Fanale M, Puhlmann M, Iyer S. Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Adv. 2022 Oct 11;6(19):5550-5555. doi: 10.1182/bloodadvances.2020003971. Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illes A, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Huttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trumper L; ECHELON-2 Study Group. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Erratum In: Lancet. 2019 Jan 19;393(10168):228. doi: 10.1016/S0140-6736(18)33123-4. Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, Illidge T, Huebner D, Kennedy DA, Shustov AR. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study. J Clin Oncol. 2014 Oct 1;32(28):3137-43. doi: 10.1200/JCO.2013.54.2456. Epub 2014 Aug 18.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Thomas Manley, MD
Query!
Address
0
0
Seagen Inc.
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Type
Other Details
Attachment
Study protocol
https://cdn.clinicaltrials.gov/large-docs/52/NCT01777152/Prot_000.pdf
Statistical analysis plan
https://cdn.clinicaltrials.gov/large-docs/52/NCT01777152/SAP_001.pdf
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT01777152
Download to PDF